Why Manitowoc, Endocyte, and Seattle Genetics Tumbled Today

Stocks generally disappointed investors on Friday as the Ukrainian situation trumped strong jobs data, but these three stocks performed much worse than the broader market. Find out why.

May 2, 2014 at 8:35PM
Longview

Stocks closed modestly lower Friday, as violence in Ukraine's third-largest city raised the chances of more aggressive Russian intervention and whatever response Western nations would make to such a move. Favorable jobs data helped counteract the impact of geopolitical tension somewhat, but Manitowoc (NYSE:MTW), Endocyte (NASDAQ:ECYT), and Seattle Genetics (NASDAQ:SGEN) all fell much more sharply than the broader stock market, as troubling news affected their respective businesses.

Manitowoc fell 10% after the company reported surprising weakness in its crane-manufacturing segment. Although Manitowoc saw adjusted earnings jump 62% from the year-ago quarter, revenue fell 5%, with an even greater 14% drop in crane sales offsetting strength in Manitowoc's foodservice equipment division. Investors weren't satisfied with Manitowoc's reiteration of its full-year guidance, even though it implies that the company expects to make up for any shortfall during the remainder of the year. With other construction-equipment companies reporting more favorable results, investors will have to decide whether Manitowoc's results are a one-time aberration or a sign that its rivals are doing a better job of capturing opportunities in the recovering construction market.

Mtw
Source: Manitowoc.

Endocyte plunged 62% after the company announced a setback for its vintafolide treatment. Endocyte had received a positive opinion for condition marketing authorization for the drug by the European Committee for Medicinal Products for Human Use earlier this year, raising hopes for the company's future. But a data safety monitoring board covering a phase 3 trial of Endocyte's vintafolide in the U.S. recommended that the trial be stopped because it hadn't met its goal of greater progression-free survival for platinum-resistant ovarian-cancer patients. With the bad news, Endocyte will have to work with its partner to determine whether to keep developing vintafolide, or concentrate on other opportunities.

Seattle Genetics dropped 11% even as the biotech announced solid revenue growth in its first-quarter results last night. Sales for Seattle Genetics rose 19%, with just about all of its revenue coming from product sales and affiliated revenue related to its Adcetris antibody-drug conjugate, which has thus far received FDA approval to treat Hodgkin's lymphoma and anaplastic large-cell lymphoma. Yet, even those results weren't enough to satisfy Seattle Genetics shareholders, and guidance for the full year suggested that Adcetris' upside could be far more limited than investors previously thought. Although the technology behind antibody-drug conjugates has great potential, Seattle Genetics will need to capitalize on that potential in order to reassure shareholders.

You don't want to miss this
The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next trillion dollar industry." And everyone from BMW, to shoemakers, to the U.S. Air Force is already using it every day. Watch The Motley Fool's shocking video presentation today to discover the garage gadget that's putting an end to the Made In China era... and learn the investing strategy we've used to double our money on these three stocks. Click here to watch now!

Dan Caplinger has no position in any stocks mentioned. The Motley Fool recommends Seattle Genetics. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers